User contributions for Parth Vikram Singh
Results for Parth Vikram Singh talk block log uploads logs
A user with 1,531 edits. Account created on 28 January 2025.
25 April 2025
- 16:1416:14, 25 April 2025 diff hist 0 N File:Next2.png No edit summary current
- 16:1316:13, 25 April 2025 diff hist 0 N File:Next1b.png No edit summary current
- 16:1316:13, 25 April 2025 diff hist 0 N File:Next1a.png No edit summary current
- 16:1216:12, 25 April 2025 diff hist 0 N File:Nexstr2.png No edit summary current
- 16:1216:12, 25 April 2025 diff hist 0 N File:Nexstr1.png No edit summary current
- 16:1216:12, 25 April 2025 diff hist 0 N File:Nexpkg.png No edit summary current
- 16:0916:09, 25 April 2025 diff hist 0 N File:Nexf1.png No edit summary
- 13:5013:50, 25 April 2025 diff hist +1,594 N Drospirenone and estetrol Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=drospirenone and estetrol |aOrAn=a |drugClass=combination of drospirenone, a progestin, and estetrol, an estrogen, |indicationType=treatment |indication=reproductive potential to prevent pregnancy |hasBlackBoxWarning=Yes |adverseReactions=bleeding irregularities, mood disturbance, headache, breast symptoms, dysmenorrhea, acne, weight increased, and libido decreased . |blackBoxWarningTitle='''<span style="color:#..."
- 13:4113:41, 25 April 2025 diff hist +3,864 Dostarlimab-gxly No edit summary current
- 13:1913:19, 25 April 2025 diff hist +216 Dostarlimab-gxly No edit summary
- 11:3011:30, 25 April 2025 diff hist +3,225 Dostarlimab-gxly No edit summary
- 11:2311:23, 25 April 2025 diff hist +49,694 Dostarlimab-gxly No edit summary
- 10:5110:51, 25 April 2025 diff hist +21,391 Dostarlimab-gxly No edit summary
- 07:2507:25, 25 April 2025 diff hist +51 Dostarlimab-gxly No edit summary
- 06:5206:52, 25 April 2025 diff hist 0 N File:Jemt12b.png No edit summary current
- 06:5206:52, 25 April 2025 diff hist 0 N File:Jemt12a.png No edit summary current
- 06:5206:52, 25 April 2025 diff hist 0 N File:Jemt11.png No edit summary current
- 06:5106:51, 25 April 2025 diff hist 0 N File:Jemt10.png No edit summary current
- 06:5106:51, 25 April 2025 diff hist 0 N File:Jemt9b.png No edit summary current
- 06:5106:51, 25 April 2025 diff hist 0 N File:Jemt9a.png No edit summary current
- 06:5006:50, 25 April 2025 diff hist 0 N File:Jemt8b.png No edit summary current
- 06:5006:50, 25 April 2025 diff hist 0 N File:Jemt8a.png No edit summary current
- 06:5006:50, 25 April 2025 diff hist 0 N File:Jemt7b.png No edit summary current
- 06:4906:49, 25 April 2025 diff hist 0 N File:Jemt7a.png No edit summary current
- 06:4906:49, 25 April 2025 diff hist 0 N File:Jemt6.png No edit summary current
- 06:4906:49, 25 April 2025 diff hist 0 N File:Jemt5b.png No edit summary current
- 06:4806:48, 25 April 2025 diff hist 0 N File:Jemt5a.png No edit summary current
- 06:4806:48, 25 April 2025 diff hist 0 N File:Jemt4b.png No edit summary current
- 06:4706:47, 25 April 2025 diff hist 0 N File:Jemt4a.png No edit summary current
- 06:4706:47, 25 April 2025 diff hist 0 N File:Jemt3b.png No edit summary current
- 06:4706:47, 25 April 2025 diff hist 0 N File:Jemt3a.png No edit summary current
- 06:4606:46, 25 April 2025 diff hist 0 N File:Jemt2b.png No edit summary current
- 06:4606:46, 25 April 2025 diff hist 0 N File:Jemt2a.png No edit summary current
- 06:4606:46, 25 April 2025 diff hist 0 N File:Jempkg.png No edit summary current
- 06:4506:45, 25 April 2025 diff hist 0 N File:Jemf3.png No edit summary current
- 06:4506:45, 25 April 2025 diff hist 0 N File:Jemf2.png No edit summary current
- 06:4406:44, 25 April 2025 diff hist 0 N File:Jemf1.png No edit summary current
- 06:4306:43, 25 April 2025 diff hist 0 N File:Jemdose.png No edit summary current
24 April 2025
- 11:5311:53, 24 April 2025 diff hist +17,779 N Dostarlimab-gxly Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=dostarlimab-gxly |aOrAn=a |drugClass=death receptor-1 (PD-1)–blocking antibody |indicationType=treatment |indication=*adult patients with primary advanced or recurrent endometrial cancer (EC). *adult patients with mismatch repair deficient (dMMR) recurrent or advanced EC, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any settin..."
- 11:2211:22, 24 April 2025 diff hist 0 Loncastuximab tesirine-lpyl No edit summary current
- 11:1811:18, 24 April 2025 diff hist 0 N File:Lont2.png No edit summary current
- 11:1611:16, 24 April 2025 diff hist 0 N File:Lont4.png No edit summary current
- 11:1611:16, 24 April 2025 diff hist 0 N File:Lont3.png No edit summary current
- 11:1511:15, 24 April 2025 diff hist 0 N File:Lont1.png No edit summary current
- 11:1411:14, 24 April 2025 diff hist 0 N File:Lonstr.png No edit summary current
- 11:1411:14, 24 April 2025 diff hist 0 N File:Lonpkg.png No edit summary current
- 11:1311:13, 24 April 2025 diff hist 0 N File:Londose.png No edit summary current
- 11:1211:12, 24 April 2025 diff hist 0 N File:Lomt2.png No edit summary current
- 11:1111:11, 24 April 2025 diff hist +3,300 Loncastuximab tesirine-lpyl No edit summary
- 10:5710:57, 24 April 2025 diff hist +21 Loncastuximab tesirine-lpyl No edit summary
